Landscape of Transcriptional Deregulations in the Preeclamptic Placenta

Daniel Vaiman, Rosamaria Calicchio, Francisco Miralles*
INSERM U1016-CNRS UMR8104, Université Paris Descartes, Institut Cochin, Paris, France

Abstract

Preeclampsia is a pregnancy disease affecting 5 to 8% of pregnant women and a leading cause of both maternal and fetal morbidity and mortality. Because of a default in the process of implantation, the placenta of preeclamptic women undergoes insufficient vascularization. This results in placental ischemia, inflammation and subsequent release of placental debris and vasoactive factors in the maternal circulation causing a systemic endothelial activation. Several microarray studies have analyzed the transcriptome of the preeclamptic placentas to identify genes which could be involved in placental dysfunction. In this study, we compared the data from publicly available microarray analyses to obtain a consensus list of modified genes. This allowed to identify consistently modified genes in the preeclamptic placenta. Of these, 67 were up-regulated and 31 down-regulated. Assuming that changes in the transcription level of co-expressed genes may result from the coordinated action of a limited number of transcription factors, we looked for over-represented putative transcription factor binding sites in the promoters of these genes. Indeed, we found that the promoters of up-regulated genes are enriched in putative binding sites for NFkB, CREB, ANRT, REEB1, SP1, and AP-2. In the promoters of down-regulated genes, the most prevalent putative binding sites are those of MZF-1, NFYA, E2F1 and MEF2A. These transcription factors are known to regulate specific biological pathways such as cell responses to inflammation, hypoxia, DNA damage and proliferation. We discuss here the molecular mechanisms of action of these transcription factors and how they can be related to the placental dysfunction in the context of preeclampsia.

Introduction

Preeclampsia (PE) is a pregnancy complication affecting approximately 5–8% of pregnant women and capable of causing both maternal and fetal morbidity and mortality. The disease develops after 20 weeks of gestational age and is characterized by elevated maternal blood pressure (140 mmHg/90 mmHg) and proteinuria (>300 mg/24h), endothelial cells (ECs) dysfunction and systemic inflammation [1]. In addition, PE can lead to eclampsia (when convulsions develop), and may be associated with the HELLP syndrome (Hemolysis, Elevated Liver enzymes and Low Platelet count). Both conditions may induce severe complications such as cerebral hemorrhage, lung edema or liver hemorrhage and rupture. PE symptoms appear after 20 weeks of gestational age, but sometimes much later by the end of pregnancy, and even, quite surprisingly, post-partum [2]. Those PEs who initiate early are generally more severe (blood pressure >160 mmHg/110 mmHg and proteinuria >300 mg/24h) and associated to a greater rate of intrauterine growth retardation and of iatrogenic prematurity.

Defective placentation is generally described as being at the root of the disease. Several studies have established that in the developing preeclamptic placenta, the normal process of trophoblast invasion and remodeling of the uterine maternal spiral arteries is impaired. This default in placental development in early pregnancy results in reduced placental perfusion, placental oxidative stress and inflammation, with subsequent release of placent al factors and debris into the maternal circulation. These circulating factors are supposed to cause a widespread ECs activation leading to the multisystem dysfunction characteristic of the maternal syndrome of PE [3,4]. Since the placenta plays a central role in the development of the disease, identifying the molecular mechanisms altered in the preeclamptic placenta comparatively to the non-pathologic placenta is fundamental to understand the initiation and evolution of this disease. In this context microarray-based genome-wide transcriptional profiling was used in several studies based on the comparison of the preeclamptic and non-pathologic placenta as reviewed by Louwen and collaborators [5]. In general, similar categories of differentially-expressed genes were reported including genes involved in: vascular regulation, inflammation, cell proliferation, apoptosis, differentiation, and cellular metabolism. However, in some cases the results appeared controversial in respect to some of the genes of interest. These differences may originate from the type of PE, the sampling of the placenta, the gestational age, ethnicity, mode of delivery, the microarray platforms and the filtering and statistical analysis. To overcome these differences we compared the lists of modified genes extracted from the publicly available datasets on microarray experiments concerning the preeclamptic placenta. The intersection of these gene-expression data sets, considering both up- and down-regulated genes, allowed obtaining...
a minimal list of genes which are consistently modified in PE. Then, we have used this consensus list to explore the transcriptional mechanisms involved in preeclampsia-specific placental dysfunction. This strategy has been used recently by Tapia and coworkers to identify with success transcription factors (TFs) involved in endometrial receptivity [6]. Transcriptional mechanisms control the expression of genes mainly through the action of TFs. These proteins bind to the DNA regulatory sequences of the genes at specific sites known as transcription factor binding sites (TFBS). Usually, the transcriptional activity of a gene requires the binding of several TFs, which act cooperatively to activate or repress transcription [7]. Therefore, we have used several bioinformatic tools allowing detecting over-representation of TFBS and of sets of TFBS in the promoters of genes. This way we identified a number of TFs which are likely involved in the regulation of the set of consistently modified genes in PE. These TFs may be instrumental in the transcriptomic modifications undergone by the preeclamptic placenta and their involvement in this disease can now be tested in the wet laboratory.

**Materials and Methods**

**Data Sets used in this Study**

We searched the public DataSets assembled from the Gene Expression Omnibus (GEO) repository, to identify expression microarray datasets that compared the expression of preeclamptic versus normal placentas. The keywords: preeclampsia, placenta, microarrays and gene-expression, were used for this search. To be included in our study the microarray experiments had to be done with placental biopsies collected at delivery and at relatively comparable gestational ages (30–39 weeks). This allowed to identify six datasets (Table 1). The GEO accession numbers of the studies are: GSE10588, GSE4707, GSE30186, GSE25906, GSE24129 and GSE14722, [8,9,10,11,12,13]. The data from each study were analyzed with Geo2R to identify genes undergone by the preeclamptic placenta and their involvement in the disease can now be tested in the wet laboratory.

### Table 1. Preeclamptic placenta microarrays analyzed in this study.

| Study                  | GEO accession | PE samples | Co samples | PE/Co Gest. Age (Weeks) | Delivery | Microarrays platform        |
|------------------------|---------------|------------|------------|-------------------------|----------|-----------------------------|
| Sitrats et al., 2009 [9] | GSE10588      | 17         | 26         | 34/39                   | CS       | ABI HGSM Version 2          |
| Nishizawa et al., 2007 [12] | GSE4707       | 13         | 8          | 32/32                   | CS       | Agilent-012391 Whole Human Genome Oligo Microarray G4112A |
| Meng et al., 2011 [10]  | GSE30186      | 6          | 6          | 36/39                   | CS       | Illumina HumanHT-12 V4.0    |
| Tsai et al., 2011 [11]  | GSE25906      | 23         | 37         | 33/37                   | Labor    | Illumina human-6 v2.0       |
| Nishizawa et al., 2011 [13] | GSE24129      | 8          | 8          | 34/38                   | CS       | Affymetrix Human Genome 1.0 ST Array |
| Win et al., 2009 [14]   | GSE14722      | 12         | 11         | 32/31                   | CS/Labor | Affymetrix Human Genome U133 Plus 2.0 |

*Gestational age (weeks).

doi:10.1371/journal.pone.0065498.t001

**Functional Clustering**

The list of genes consistently up- and down-regulated with the microarray datasets was submitted to the GENOMATIX GeneRANKer tool for functional annotation and pathway analysis. This allowed gaining information on the biological significance of these genes.

**Identification of Over-represented TFBS in the Proximal Promoter of the Genes Consistently Modified in the Preeclamptic Placenta**

The sequences of the proximal promoter of the genes associated with the preeclamptic placenta were retrieved from the Data Base of Transcriptional Start Sites (DBTSS), [14]. For the purposes of this study the proximal promoter was defined as the region comprised within 1000 base pairs (bp) upstream and 200 bp downstream of the transcriptional start site (TSS). These sequences were used to search for potential TFBS using the following free softwares: CREMAG, a web tool that searches over-represented TFBS in a set of sequences using the TRANSFAC and JASPAR vertebrate position-weight matrices [15]. The analysis was performed with the default parameters. We used a 70% conservation threshold and a maximum number of 20 most conserved TFBSs in non-coding regions between 1000 bp upstream and 200 bp downstream of the TSS. TELIS (Transcription Element Listening System) is a Java server-side application which identifies transcription-factor binding motifs (TFBMs) that are over-represented among the promoters [16]. It consists of two parts: PromoterScan and PromoterStats. PromoterScan finds the number of occurrences of specific TFBMs in promoters and stores the results in MySQL database. PromoterStats uses z-statistics to find matrices which are over-represented (or under-represented) on the specific differentially expressed promoter set.

The transcription factor affinity prediction (TRAP) method calculates the affinity of transcription factors for DNA sequences on the basis of a biophysical model [17]. This method has proven to be useful for several applications, including for determining which transcription factors have the highest affinity in a set of sequences [18]. TFM-explorer is a program for analyzing regulatory regions of eukaryotic genomes. It takes a set of co-regulated gene sequences, and search for locally over-represented TFBS [19]. The algorithm proceeds in two steps: (i) it scans sequences for detecting all potential transcription factor binding sites, using weight matrices from JASPAR or TRANSFAC. (ii) it extracts significant clusters (region of the input sequences associated with a factor) by calculating a score function. The web tool TOUCAN uses the MotifScanner algorithm to search for
potential TFBS in a set of sequences using the TRANSFAC or JASPAR vertebrate databases. The information obtained from the MotiScanner is subsequently processed by the statistics function of TOUCAN to identify over-represented TFBS [20,21]. We used several different TFBS prediction software’s because these bioinformatics tools usually generate a number of false positives. Thus, only TFBS predicted by more than one tool were considered as true positives.

Identification of Regulatory Modules

To identify common regulatory modules in a set of promoter sequences we used the Genomatix FrameWorker software. FrameWorker identifies significant complex models of TFBS present in the promoter sequences of a set of co-regulated genes. The models/FrameWorkers are defined as all the TFBS that occur in the same order and in a certain distance range in all (or a subset) of the input sequences. To determine the P-value of the models, a background promoter sequence set of 5000 human promoters is scanned with the models generated by the software. This allows calculating the probability to found the same models in a set of randomly selected promoters.

Transcription Factors Interaction

TFs interactions were identified through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database v9.0. This database contains known and predicted physical and functional protein-protein interactions [22]. STRING was used in the protein mode, and only interactions based in experimental protein-protein interaction and curated databases with confidence levels over 0.5 were considered.

Results

Identification of Genes Consistently Associated with the Preeclamptic Placenta

The intersection of the lists of modified genes extracted from the microarray studies of the preeclamptic placenta yielded a short list of genes being consistently modified in the different studies. We identified a total 98 modified genes of which 67 were up-regulated and 31 down-regulated. Table 2 (up-regulated) and Table 3 (down-regulated) show a selection of consistently modified genes in PE. Complete lists are provided as Tables S1 and S2. The most consistently up-regulated genes were LEP and FLT1 [present in the totality of studies], followed by QPCT, SIGLEC6, ENG, BCL6, INHA, EB13, PAPP2 and HTRA1 [found modified in five studies]. The most consistently down-regulated gene modified in all the studies was CLDN1. Followed by genes present at least in four out of six studies including among others ABAT, SOD1, GCLM, APLN, ABCG2, and NR2F1.

Functional Clustering Analysis

We then used the GENOMATIX Gene Ranker software to perform functional and network analysis of the consistently modified genes. This made it possible to identify functional gene classifiers (Table 4 and 5) and pathways (Table 6) that are significantly enriched in the preeclamptic placenta. Among the up-regulated genes the most significant functional categories were signaling and signal transduction, the regulation of biological quality, interferon-gamma biosynthetic process, the regulation of B cell differentiation and cell proliferation. The list of down-regulated genes was enriched in transcripts involved in the response to regulation of sulfur metabolism, blood vessel size and blood circulation, cellular homeostasis, and the responses to chemical stimulus and oxidative stress. The pathways with the highest scores include the peroxisome proliferative activated receptor alpha, lipid, hypoxia inducible factor 1, FMS like receptor tyrosine kinase 3 and vascular endothelial growth factor pathways. In addition, we noticed that in at least three out of the six microarray studies some of the consistently modified genes in the preeclamptic placenta encode TFs. Among the up-regulated genes we found: LIMD1 (LIM domain-containing protein 1), BHLHE40 (Basic helix-loop-helix family member e40), VDR (Vitamin D 1,25-dihydroxyvitamin D3 receptor), CEBPA (CCAAT/enhancer binding protein, alpha), BCL6 (B-cell CLL/lymphoma 6), ARID3A (AT rich interactive domain 3A) and NRIP1 (Nuclear receptor interacting protein 1). Among the down-regulated genes: TFDP2 (Transcription factor Dp-2), ZFAND5 (Zinc finger, AN1-type domain 5), BHLHE41 (Basic helix-loop-helix family, member e41), and NR2F1 (Nuclear receptor subfamily 2, group F, member 1). These TFs were also included in further analyses.

Identification of Over-represented TFBS among the Consistently Modified Genes

Co-expressed groups of genes are expected to share regulatory elements which are responsible of the co-regulation. Thus, to identify the putative common regulatory elements the lists of up- and down-regulated genes were analyzed with bioinformatics tools. First the proximal promoter sequences of the genes (1000 bp up-stream and 200 bp downstream of the TSS) were retrieved from the DBTSS data base, and subsequently analyzed with several public TFBS detection tools: CREMAG, TELIS, TRAP, TFM-Explorer, and TOUCAN. Only those TFBS showing a P value ≤0.05 for their observed frequency versus their predicted frequency were considered. The results of these analysis are listed in Table 7 and Table 8. The most significant over-represented TFBS found in the up-regulated genes list correspond to NFkB (Nuclear factor kappa B), RREB1 (Ras responsive element binding protein 1), SP1 (Specificity protein 1), ARNT (Aryl hydrocarbon receptor nuclear translocator), CREB1 (cAMP responsive element binding protein 1) and AP-2 (Activating enhancer-binding protein 2). In the down-regulated list the most significant over-represented TFBS are MZF1 (Myeloid zinc finger 1), E2F1 (E2F transcription factor 1), MEF2A (Myocyte enhancer domain family member 2A) and NFYA (Nuclear transcription factor Y, alpha). Some TFBS, such as SP1, E2F1, ARNT, and MZF1 appear over-represented in both up- and down-regulated genes.

Search for Regulatory Modules in TFs Consistently Modified in Preeclampsia

The intersection of the microarrays of preeclamptic placentas indicates that a few TFs appear consistently modified at the transcriptional level (either up- or down-regulated). Thus, these transcriptionally co-regulated TFs could share common regulatory elements in their promoters. These elements are often organized into defined motifs (frameworks) of two or more TFBS which are located in the promoter of the genes in a specific orientation, separated by a given distance and working in concert. We used the Genomatix FrameWorker software to identify putative regulatory modules among the TFs consistently modified in the preeclamptic placenta. Among the promoter sequences of the TFs consistently up-regulated we got seven significant models (i.e. modules) of three elements present in the promoter of five genes out of seven. The most significant model (P=7.82×10^-11) was composed of TFBS for the Zinc finger transcription factors EGRF (Early growth response family), E2FF (E2F-myc activator/cell cycle regulator) and ZF5F (binding site for the transcription factor Zifp161);
In addition, an alternative regulatory module of two elements (EGRF and E2FF) was found present in the promoter of six out of the seven TFs consistently up-regulated in the preeclamptic placenta ($P \leq 8.76 \times 10^{-10}$). In the case of the consistently down-regulated TFs we found one highly significant model ($P \leq 1.99 \times 10^{-10}$) composed of six elements corresponding to TFBS for E2FF, RXRF (Retinoid × receptor heterodimer-binding sites), KLFS (Kruppel-like factors) and ZF02 (C2H2 zinc finger transcription factors 2). This module was present in the promoter of three out of four genes (Figure 1B).

Table 2. Partial list of consistently up-regulated genes in the preeclamptic placenta.

| Gene   | Ensembl Gene ID | GSE4707 | GSE24129 | GSE10588 | GSE25906 | GSE14722 | GSE30186 |
|--------|-----------------|---------|----------|----------|----------|----------|----------|
| LEP    | 3952            | 1       | 1        | 1        | 1        | 1        | 1        |
| FLT1   | 2321            | 1       | 1        | 1        | 1        | 1        | 1        |
| HTRA1  | 5654            | 1       | 1        | 1        | 1        | 1        | -        |
| QPCT   | 25797           | 1       | 1        | 1        | 1        | 1        | 1        |
| SPAG4  | 6676            | 1       | 1        | 1        | 1        | 1        | -        |
| INHA   | 3623            | 1       | 1        | 1        | 1        | 1        | -        |
| PAPPA2 | 60676           | 1       | 1        | 1        | 1        | 1        | -        |
| SIGLEC6| 946             | 1       | 1        | 1        | 1        | 1        | -        |
| ENG    | 2022            | 1       | 1        | 1        | 1        | 1        | -        |
| INHBA  | 3624            | 1       | 1        | 1        | 1        | 1        | -        |
| BCL6   | 604             | -       | 1        | 1        | 1        | 1        | -        |
| SLC26A6| 65010           | -       | 1        | 1        | 1        | -        | 1        |
| GREM2  | 64388           | 1       | 1        | 1        | 1        | 1        | -        |
| EB13   | 10148           | 1       | 1        | 1        | 1        | 1        | -        |
| HTRA4  | 203100          | 1       | 1        | 1        | 1        | -        | -        |
| FSTL3  | 10272           | 1       | 1        | 1        | 1        | -        | -        |
| BHLHE40| 8553            | 1       | 1        | 1        | 1        | -        | -        |

The table shows some of the consistently up-regulated genes in the six preeclamptic placenta microarray studies analyzed. The microarrays are identified by their GEO data set accession number (GSE). (1) Indicates modified in the microarrays, (-) Indicates not-modified. *Complete consensus list of up-regulated genes in the preeclamptic placenta is provided as Table S1.

Table 3. Partial list of consistently down-regulated genes in the preeclamptic placenta.

| Gene   | Ensembl Gene ID | GSE4707 | GSE24129 | GSE10588 | GSE25906 | GSE14722 | GSE30186 |
|--------|-----------------|---------|----------|----------|----------|----------|----------|
| CLDN1  | 9076            | 1       | 1        | 1        | 1        | 1        | 1        |
| ABAT   | 18              | 1       | 1        | 1        | 1        | -        | 1        |
| MIF    | 56947           | -       | 1        | 1        | 1        | 1        | -        |
| GCLM   | 2730            | -       | 1        | 1        | 1        | 1        | 1        |
| F13A1  | 2162            | -       | 1        | 1        | 1        | 1        | -        |
| SOD1   | 6647            | -       | 1        | 1        | 1        | 1        | -        |
| APLN   | 8862            | 1       | 1        | 1        | -        | 1        | -        |
| ABCG2  | 9429            | -       | 1        | 1        | 1        | 1        | -        |
| GOT1   | 2805            | -       | 1        | 1        | 1        | 1        | -        |
| SLC23A2| 9962            | -       | 1        | 1        | 1        | -        | 1        |
| QLFML3 | 56944           | -       | 1        | -        | 1        | 1        | 1        |
| LEPREL | 55214           | 1       | 1        | 1        | 1        | -        | 1        |
| BHLHE41| 79365           | -       | 1        | 1        | -        | 1        | -        |
| FAM101B| 359845          | 1       | 1        | 1        | 1        | -        | -        |
| NR2F1  | 7025            | -       | 1        | 1        | 1        | 1        | -        |

The table shows some of the consistently down-regulated genes in the six preeclamptic placenta microarray studies analyzed. The microarrays are identified by their GEO data set accession number (GSE). (1) Indicates modified in the microarrays, (-) Indicates not-modified. *Complete consensus list of down-regulated genes in the preeclamptic placenta is provided as Table S2.
Transcription Factors Interactome

We used the STRING database to search for known interactions among the TFs identified as consistently modified in the preeclamptic placenta and also with those identified through our TFBS analysis. Subsequently, we used the STRING functions to extend the network and display close interacting factors. As shown in Figure 2, the majority of the TFs modified in the preeclamptic placenta including those inferred from the TFBS analysis present a close functional association. In addition, we identified that the transcription factor EP300 (E1A binding protein p300) is connected with the largest number of preeclampsia-associated TFs in an extended interaction network.

Discussion

The molecular basis of transcriptional alterations in the preeclamptic placenta remains elusive. Herein, we identified several TFs which are putatively involved in the regulation of genes that are consistently associated with PE. We started our analysis by intersecting publicly available datasets from microarrays analysis of preeclamptic placentas. This allowed building a consensus list of modified genes in the preeclamptic placenta. Of these, 67 were up-regulated and 31 down-regulated. The functional analysis identified several categories including: signaling, biological quality regulation, myeloid cell regulation, and cell proliferation among the up-regulated genes. Blood vessel regulation, blood circulation, cellular homeostasis and response to oxidative stress were the functional categories identified as enriched in the down-regulated genes. Consistently with preeclampsia pathophysiology, pathway analysis showed an over-representation of genes involved in peroxisome proliferative activated receptor alpha, lipid biosynthesis, hypoxia, and VEGF response. Subsequently, we extended our analysis by searching common TFs possibly involved in gene regulation in preeclamptic women’s placentas. Several bioinformatics tools detected over-represented TFBSs in the promoters of the PE-associated genes. Inside up-regulated genes promoters we found an over-representation of TFBSs for NFKB, SP1, RREB1, ARNT, CREB1 and AP-2. Conversely, among the down-regulated genes we found a prevalence of TFBSs for MZF-1, NFYA, E2F1 and MEF2A. Interestingly several transcriptionally modified genes were themselves transcription factors. Below, we discuss the molecular mechanisms of action of all these TFs, and how they might be related to the placental dysfunction in the context of PE.

NFκB. Belongs to the REL family of TFs which in mammals is composed of five members: RelA/p65, RelB, c-Rel, p50(NFkB1), p105(NFkB2), and p100(NFkB1/p105). NFKB may bind to an array of DNA sequences in the presence of its activator protein-1 (AP-1) and act as a transcriptional activator of many genes. The association between NFκB and oxidative stress has been recently well characterized, and NFκB is a key regulator of inflammation, stress responses, apoptosis, cell proliferation, and angiogenesis.

Table 4. Biological processes annotation clusters for up-regulated genes as reported by the GENOMATIX webtool.

| Database   | Functional annotation       | N' of genes | Genes                                                                 | P-Value  |
|------------|----------------------------|-------------|----------------------------------------------------------------------|----------|
| GO:0023052 | Signaling                  | 36          | HTRA1, HEXB, CEBPA, DDR1, LYN, CYP26A1, ENG, APLP2, EBi3, KIT, HLPDA, SYDE1, RASEF, PREX1, BAD, VDR, INSG1, FLT1, LHB, FSTL3, SCARB1, LIMD1, MIF, BHLHE40, SIGLEC6, TREM1, LEP, GREM2, ERRF11, NRIP1, INHBA, CORO2A, ERO1L, INHA, SHSBPS, NEX111 | 1.73E-06 |
| GO:0065008 | Regulation of biological quality | 25        | HTRA1, HEXB, DDR1, LYN, CYP26A1, ENG, APLP2, BCL6, KIT, GAPDH, E2R, BAD, VDR, KIF2A, LHB, HTRA4, SCARB1, BHLHE40, PAPP2A, TREM1, LEP, INHBA, INHA, HK1, PROC | 3.42E-06 |
| GO:0030099 | Myeloid cell differentiation | 7           | CEBPA, LYN, KIT, FSTL3, LEP, INHBA, INHA7 | 7.47E-06 |
| GO:0007165 | signal transduction        | 32          | HTRA1, CEBPA, DDR1, LYN, CYP26A1, ENG, APLP2, EBi3, KIT, SYDE1, RASEF, PREX1, BAD, VDR, INSG1, FLT1, LHB, FSTL3, SCARB1, LIMD1, MIF, TREM1, LEP, GREM2, ERRF11, NRIP1, INHBA, CORO2A, ERO1L, INHA, SHSBPS, NEX111 | 1.72E-05 |
| GO:0045577 | B cell differentiation     | 3           | BAD, INHBA, INHA1 | 1.81E-05 |
| GO:0022414 | Reproductive process       | 15          | GPX3, HEXB, DDR1, APLP2, KIT, IGSF8, VDR, FLT1, LHB, LEP, NRIP1, INHBA, SPAG4, INHA, HK2 | 2.74E-05 |
| GO:0045072 | Interferon-gamma biosynthesis | 3           | EBI3, INHBA, INHA2 | 2.98E-05 |
| GO:0008283 | Cell proliferation         | 16          | CEBPA, DDR1, LYN, ENG, EBi3, KIT, HLPDA, IGsf8, BAD, VDR, INSG1, FLT1, SCARB1, MIF, INHBA, INHA | 5.99E-05 |

doi:10.1371/journal.pone.0065498.t004

Table 5. Biological processes annotation clusters for down-regulated genes as reported by the GENOMATIX webtool.

| Database   | Functional annotation       | N' of genes | Genes                                                                 | P-Value |
|------------|----------------------------|-------------|----------------------------------------------------------------------|---------|
| GO:0006790 | Sulfur compound metabolism | 4           | GCLM, SOD1, ENPP1, GOT1 | 1.41E-04 |
| GO:0050880 | Regulation of blood vessel size | 3         | GCLM, SOD1, APLN | 5.71E-04 |
| GO:0006536 | Glutamate metabolic process | 2           | GCLM, GOT1 | 4.03E-04 |
| GO:0006979 | Response to oxidative stress | 4           | GCLM, SOD1, SL23A2, SEPP1 | 4.85E-04 |
| GO:0008015 | Blood circulation          | 4           | GCLM, ABAT, SOD1, APLN | 1.34E-03 |
| GO:042311  | Vasodilation               | 2           | APLN, SOD1 | 2.17E-03 |
| GO:0065008 | Regulation of biological quality | 10        | HSD17B1, GCLM, SOD1, APLN, ABCC2, F13A1, ABAT, NRCAM, ENPP1, GOT1 | 3.15E-03 |

doi:10.1371/journal.pone.0065498.t005
NFκB proteins bind to kB sites as dimers, either homodimers or heterodimers, and can exert both positive and negative effects on gene transcription. Signaling mediated by NFκB stimulates inflammation, invasion, angiogenesis, and cell proliferation and it is also associated with apoptosis regulation [23]. NFκB is known to be involved in PE at several levels and in different cell types. Placental NFκB has been found activated nearly 10-fold in PE [24]. In vitro experiments show that oxidative

| Pathway                                      | N° of genes | Observed genes       | P-value   |
|----------------------------------------------|-------------|----------------------|-----------|
| Peroxisome Proliferative Activated Receptor Alpha | 5           | VDR, LHB, SCARB1, LEP, NRIP1 | 5.04E-05  |
| Lipid                                        | 8           | LYN, PREX1, EZR, SCARB1, LEP, ARID3A, HK2, PROCRA | 2.97E-04  |
| Hypoxia inducible Factor 1, alpha subunit    | 4           | NDRG1, FLT1, MIF, ERO1L | 2.02E-03  |
| F5M Like Receptor Tyrosine Kinase 3           | 3           | CEBPA, LYN, KIT     | 2.71E-03  |
| Vascular Endothelial Growth Factor           | 5           | ENG, KIT, PREX1, FLT1, ERO1L | 3.08E-03  |
| Nuclear Receptor Subfamily 1, Group H        | 2           | VDR, SCARB1         | 4.60E-03  |
| BCL2 Associated Anthogene                    | 2           | BAD, VDR            | 8.15E-03  |
| Chemokine (CXC Motif) Receptor 4             | 3           | KIT, PREX1, MIF     | 9.09E-03  |
| TEK Tyrosine Kinase                          | 2           | ENG, FLT1           | 9.83E-03  |
| Nuclear Receptor Subfamily 2, GroupF         | 1           | NRZF1               | 4.56E-03  |

Table 6. Signal transduction pathways as reported by the GENOMATIX web tool.

doi:10.1371/journal.pone.0065498.t006

| TFBS detection tools | CREMAG (1) | CREMAG (2) | TELIS (2) | TRAP (1) | TFM-explorer (1) | TFM-explorer (2) | TOUCAN (2) |
|---------------------|------------|------------|----------|----------|-----------------|-----------------|------------|
| CREB1               | REST       | GC         | INS1M1   | KLF4     | SP1             | SP1             |            |
| CEBPA               | OLF1       | AP2        | AP2      | SP1      | GC              | AP2             |            |
| NFIL3               | CEBPA      | MZF1       | KLF4     | ARNT     | MZF1            | PAX5            |            |
| HLF                 | ATF2       | NFKB       | EBF1     | MYC      | AP2             | E2F1            |            |
| ELK1                | CREB1      | ARNT       | PAX5     | RRE1B    | NFKB            | NFKB            |            |
| PAX5                | E2F1       | CREL       | RRE1B    | EGR1     | RRE1B           | MAZR            |            |
| PAX4                | E4BP4      | K2         | TP53     | MAX      | TP53            | NFA             |            |
| ATF                 | SP1        | Tcf2p1     | MYC      | MYCMA    | ATF2            |                |            |
| MZF1                | ESR1       | HIF1A      | USF      | NFK2     |                |                |            |
| SRY                 | EGR1       | SP2Z1      | HOX13    | NGFIC     |                |                |            |
| STAT3               | NFKB       | CAP        | E2F1     |          |                |                |            |
| OCT1B               | MYCMA      | BARBIE     | SP2Z1    |          |                |                |            |
| SP1                 | MZF1       | ARNT       | AP4      |          |                |                |            |
| AP1                 | REST       | MYF        | RRE1B    |          |                |                |            |
|                     |            | AP1        | GC       |          |                |                |            |
|                     |            | ESRRB      | CREB1    |          |                |                |            |
|                     |            | PLAG1      | STAF     |          |                |                |            |
|                     |            | ARNT       |          |          |                |                |            |
|                     |            | HNF4A      |          |          |                |                |            |
|                     |            | ZFX        |          |          |                |                |            |
|                     |            | E2F1       |          |          |                |                |            |
|                     |            | CREB1      |          |          |                |                |            |
|                     |            | SP2Z1      |          |          |                |                |            |
|                     |            | ESR2       |          |          |                |                |            |

Table 7. Transcription factor binding sites over-represented in the consensus list of up-regulated genes.

doi:10.1371/journal.pone.0065498.t007

TFBS with a prevalence P value ≤0.05 are shown. (1) and (2) indicate that the TFBS weight matrices used for the analysis were respectively JASPAR or TRANSFAC. TFBS predicted by more than one analysis tool appear in bold.
stress, a hallmark of preeclamptic placenta, causes NFκB activation in a trophoblast-like cell line, which is enhanced by TNF-α [24]. In addition, trophoblast cells respond to TLR3 activation by signaling through both NFκB and IRF pathways resulting in expression of inflammatory mediators and, in particular, the PE-related anti-angiogenic factor sFLT-1 [25]. In endothelial cells (ECs) preeclamptic plasma up-regulates NFκB activity by 2.5-fold compared with normal plasma [26]. This results in ECs activation. Several factors in the preeclamptic plasma induce endothelial NFκB activation, including cytokines, lipid peroxides, peroxinitrites, and shed membrane microparticles (mainly derived from apoptotic cytotrophoblasts, leukocytes and platelets), [26,27]. Increased endogenous activation of NFκB associated with TNF-α and IL-1β release has been detected in PBMC in PE as compared to normal pregnancies [28]. Several factors associated with PE have been shown to be able to induce NFκB activation including adiponectin, leptin, cytokines (TNF-α, IL-6), lipid peroxides, and agnostic auto-antibodies to the angiotensin II receptor type 1 (AT1-AA); [29,30]. Moreover experiments studying placental ischemia-reperfusion in vitro and in vivo provide strong evidence indicating that oxidative stress and ROS production can activate the NFκB signalling pathway [31]. Activation of the NFκB pathway in the placenta, together with other stress signaling pathways (p38, MAPK, JNK), results in the placental production of inflammatory mediators, apoptotic debris, and anti-angiogenic mediators.

**SP1.** is a ubiquitously expressed Zinc Finger TF that regulates the expression of thousands of genes implicated in the control of cellular processes. SP1 is also involved in chromatin remodeling through interactions with chromatin-modifying factors such as EP300 and histone deacetylases (HDACs). Although constitutively expressed, phosphorylation, acetylation, sumoylation, ubiquitylation, and glycosylation influence the transcriptional activity and stability of SP1 [32]. In the placenta, SP1 is involved in the differentiation of the cytotrophoblast and regulates the expression of several proteins including ID-1, Synctyn, the AT1 receptor, the 11beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2) and the pregnancy-specific glycoprotein 5, as well as several cullin genes involved in the dynamics of protein recycling [33]. Moreover, compound Sp1/Sp3 heterozygous mice show severely reduced spongiotrophoblast layer and a disorganized labyrinth layer. Within the spongiotrophoblast layer both spongiotrophoblast cells and trophoblast glycogen cells are reduced. Haploinsufficiency of both Sp1 and Sp3 also leads to a severe disruption of the normal labyrinth layer architecture [34]. In response to oxidative-stress induced by hypoxia, SP1 becomes activated and induces the expression of several factors including VEGFA, β-eneolase, cyclooxygenase 2, and carbonic anhydrase 9. SP1 is also involved in the inflammatory response and, together with NFκB and AP-1, up-regulates the expression of VCAM1 and ICAM1 adhesion molecules, tumor growth factor (TGFB)-β and platelet-derived growth factor (PDGF)β, and, finally, monocytes chemotactic protein-1 (MCP1) and osteopontin cytokines [29].

**AP2.** The activator protein-2 (AP-2) family consists of five members, AP-2α, AP-2β, AP-2γ, AP-2δ, and AP-2ε, encoded by different genes. These isoforms can directly transactivate their target genes by binding the same GC-rich consensus sequence [35]. AP-2α and AP-2γ are expressed in the placenta, and they control syncytiotrophoblast-specific gene expression [36,37]. In AP-2γ-deficient mice all derivatives of the trophoblast cells are formed, however both the embryo and the extraembryonic tissues are severely growth retarded. This growth retardation is based on a reduced proliferation of the cells of the ectoplacental cone and a reduced number of giant cells [39]. In addition, AP-2γ has been shown to regulate the genes for adenosine deaminase (ADA), human placental lactogen, and human chorionic gonadotropin-β.

---

**Table 8.** Transcription binding sites over-represented in the consensus list of down-regulated genes.

| TFBS detection tools | CREMAG (1) | CREMAG (2) | TELIS(2) | TRAP (1) | TFM-explorer (1) | TFM-explorer (2) | TOUCAN |
|----------------------|------------|------------|----------|-----------|-----------------|-----------------|--------|
| NRF1                 | AP1        | COUP       | MZF1     | NRF1      | CEBP            | NRF1            | AP4    |
| MZF1                 | SRF        | MZF1       | CTF      | NRF1      | MAFB            | NRF1            | ARNT   |
| PAX4                 | GC         | IFR2       | Nfatc2   | NRF1      | FOXF1           | Coup            | E2F1   |
| Evf1                 | OCT-1B     | AP4        | MYF      | FOXL1     | OCT-68          | OCT-1B          | E2F1   |
| MZF1                 | SP1        | Zfp423     | MAFB     | Gfi-1     | CREBP1          | E2F1            | MEF2A  |
| ARNT                 | Nkox25     | FoxD1      | Evf1     | MEF2A     | MEF2A           | MEF2A           | E2F1   |
| E2F1                 | E2F1       | SP1        | FoxD1    | TATA      | Hnf4            | HNF4            |        |
| E2F1                 | E2F1       | SP1        | FoxD1    | TATA      | Hnf4            | HNF4            |        |
| E2F1                 | E2F1       | SP1        | FoxD1    | TATA      | Hnf4            | HNF4            |        |
| NFYA                 |            |            |          |           | TBP             | TBP             |        |

TFBS with a prevalence P value ≤0.05 are shown, (1) and (2) indicate that the TFBS weight matrices used for the analysis were respectively JASPAR or TRANSFAC. TFBS predicted by more than one analysis tool appear in bold.

doi:10.1371/journal.pone.0065498.t008
The expressions of AP-2α and AP-2γ have been found elevated in the preeclamptic placentas in comparison with the gestational age-matched control placentas [41]. Moreover, the over expression of AP-2α or AP-2γ in an extravillous trophoblast (EVT) cell line, decreased its migratory and invasive abilities [41]. This was associated with reduced expression of protease activated receptor-1 and matrix metalloproteinases and a significant induction of plasminogen activator inhibitor-1 and the tissue inhibitor of metalloproteinase-1. The same study has shown that in this EVT cell line TNF-α (which is present at higher levels in PE) induces both AP-2α and AP-2γ expression. Thus, the over-representation of genes containing TFBS for AP-2 in our study is consistent with the reported increased expression of AP-2 in PE and its known role in trophoblasts genes regulation.

**CREB1.** The cAMP responsive element binding protein 1 (CREB1), a member of the leucine zipper family of DNA-binding proteins, is ubiquitously expressed and binds as a homodimer to the cAMP response element (CRE). In the placenta, CREB contributes to the regulation of PLGF gene expression [42]. Moreover in cytotrophoblast cells CREB, modulates human chorionic gonadotropin (hCG) gene-expression by a direct protein-protein interaction with AP-2α [43]. Also, a recent study has shown that hCG added to cytotrophoblast cells lines (JEG-3, BeWo) or to placental explants induces endogenous leptin expression. This induction appears to be mediated by CREB [44].

Figure 1. Transcription factors modules in the promoter sequences of TFs consistently modified in PE. The TFs consistently modified (either up- or down-regulated) in PE were analyzed with the Genomatix FrameWorker software to identify common regulatory modules. (A) We identified seven common significant four-element modules in the promoters of five out of seven consistently up-regulated TFs. Here we show the most significant (P<7.8×10^{-11}) regulatory module composed of TFBS for EGRF, E2FF and ZF5F. (B) We identified one significant 6-element regulatory module (P<1.9×10^{-10}) in the promoters of tree out of four TFs down-regulated in the preeclamptic placenta. This module is composed of TFBS for E2FF, RXRF, KLFs and ZFO2. doi:10.1371/journal.pone.0065498.g001
**ARNT (HIF-1β).** ARNT (aryl hydrocarbon receptor nuclear translocator) is the beta subunit (HIF-1β) of the heterodimeric transcription factor, hypoxia-inducible factor 1 (HIF-1). HIF-1 is a ubiquitous TF complex involved in the regulation of the cellular responses to oxygen deprivation (hypoxia). Under normoxic conditions the HIF-1α subunit is constitutively transcribed, translated and hydroxylated at multiple proline residues. This hydroxylation targets HIF-1α for proteasomal degradation. In hypoxia, mitochondria-derived ROS inhibits HIF-1α hydroxylation, enabling nuclear translocation, heterodimerization with the constitutively expressed ARNT (HIF-1β), binding to DNA, interaction with the co-activators p300/CBP and subsequent activation of hypoxia–responsive genes. In the developing placenta ARNT (HIF-1β) plays a critical role in cell differentiation [45]. Moreover, as a component of the HIF-1 complex ARNT (HIF-1β) regulates the expression of placental genes responsive to hypoxia.

---

**Figure 2. Transcription factors interaction network in the preeclamptic placenta.** TFs modified in the preeclamptic placenta were analyzed with STRING v9.0 to identify putative interactions. Blue lines represent the evidence for the association. The thickness of the line is proportional to the confidence level of the interaction. TFs found to be modified at the transcriptional level in the preeclamptic placenta appear in red (up-regulated) and green (down-regulated).

doi:10.1371/journal.pone.0065498.g002
Studies in both preeclamptic patients and animal models have revealed the existence of hypoxia in the preeclamptic placenta [46,47,48]. Hypoxia in PE, is believed to be the consequence of shallow invasion of the decidua by the cytotrophoblasts resulting in impaired remodeling of the spiral arteries. This leads to reduced uteroplacental blood flow causing placental hypoxia, oxidative stress, and inflammation. The analysis of placental explants and in vitro studies on cytotrophoblasts have shown that several factors involved in the maternal manifestations of the preeclampsia syndrome are transcriptionally regulated by the HIF-1 complex including Endoethlin 1 [49,50], Endoglin [51], the angiogenic factor sFLT-1 [52], Leptin [53], and the vasoconstrictors Urotensin II [54], Urocortin-2 and Urocortin-3 [55]. Therefore, the fact that the analysis of the promoters of consistently modified genes in PE reveals and over-representation of HIF-ANRT binding sites is consistent with the central role played by hypoxia in the development of PE.

**RREB1.** is a zinc finger TF that binds to RAS-responsive elements (RREs) of gene promoters [56]. In the placenta, RREB1 is expressed in the extravillous cytotrophoblasts were it could be involved in pathological repression of the human leukocyte antigen G (HLA-G). HLA-G is expressed in the human placenta and amnios, and plays an essential role in the maternal tolerance toward the fetus through the inhibition of the NK and T lymphocyte-mediated direct cytotoxicity. Both circulating HLA-G and HLA-G protein expressed in the extravillous cytotrophoblasts are reduced in PE [57,58], possibly trough oxidative stress [59]. RREB1 can inhibit expression of HLA-G by binding to RREs within the HLA-G promoter [60]. RREB1 is also involved in the response to cellular stress as it binds to the p53 gene core promoter and up-regulates p53 transcription. One known effect of the oxidative stress in PE is to cause oxidative DNA damage [61]. Thus, it is tempting to speculate that RREB1 could activate p53 gene expression in the preeclamptic placenta. However, at present there are contradictory studies concerning the up-regulation of p53 in the preeclamptic placenta [62].

**MZF1.** Myeloid zinc finger 1 (MZF1) is a member of the SCAN domain family of TFs. MZF1 is preferentially expressed in hematopoietic cells, and may be involved in the transcriptional regulation of hematopoietic-specific genes [63]. A putative role in placental physiology or pathology is currently unknown. However, the human placenta has been recognized to work as a hematopoietic organ during the embryonic and fetal development [64]. Increased hematopoietic activity in the preeclamptic placenta has been suggested [65]. On the other hand MZF1, together with SP1 and ZBTB7B has been involved in the regulation of the SERPINA3 in the cytotrophoblastic cell line JEG3 [66]. SERPINA3 is a serine protease inhibitor known to be up-regulated in human placental diseases (including PE) in association with a hypomethylation of the 5’ region of the gene [67]. Over expression of SERPINA3 in JEG-3 cells, decreased cell adhesion to the extracellular matrix and to neighboring cells, but protects them from apoptosis.

**E2F1.** The E2F family of TFs controls the expression of genes involved in cell proliferation, differentiation, apoptosis, and DNA repair. In the context of PE, a recent study has reported the up-regulation of E2F1, together with several genes involved in cell cycle progression, in peripheral blood mononuclear cells (PBMCs) isolated from severe preeclamptic women [68]. In our analysis we did not detect E2F1 among the consensus up-regulated genes in PE. However, we found that its partner, TFDP2, is down-regulated in the preeclamptic placentas. Thus down-regulation of TFDP2 might result in impaired DNA-binding of E2F1, and lead to the deregulation of genes controlled by the E2F1-TFDP2 complex. On the other hand, it has been reported that under hypoxic conditions E2F1 and p53 are up-regulated, and are able to down-regulate expression from the VEGF promoter [69]. The minimum VEGF promoter mediating transcriptional repression by E2F1, was found to be composed of an E2F1-binding site with four SP1 sites in close proximity. Of note, it is known that E2F1 and Sp1 proteins physically and functionally interact and show functional synergism in promoters having binding sites for both [70]. In ECs, E2F1 can induce the expression of FLT-1, KDR, and ANGPT2, through a mechanism involving VEGF stimulation, and both Histones and E2F1 acetylation [71]. Previous studies had shown that the expression of FLT-1 and KDR is regulated by Sp1 proteins. [72]. Thus, we find again the association between E2F1 and SP1 binding sites in the regulation of this antiangiogenic genes.

**MEF2A.** (Myocyte enhancer factor 2A) belongs to the MADS (MCM1, agamous, deficiens, SRF) family of TFs and plays a pivotal role in the development of various organ systems, including the cardiovascular system [73]. The implication of this TF in placental development or in preeclampsia has not been studied. However, its role in the control of gene expression in smooth muscle cells (SMCs) and ECs suggests that it might be involved in the vascularization of the placenta. In vascular SMCs, MEF2A has been shown to be activated via reactive oxygen species and p38 mitogen-activated protein kinase. This leads to the induction of the transcription factor KLF5 in response to angiotensin II [74]. KLF5 has been found consistently up-regulated in cardiovascular diseases [75]. Within ECs, shear stress stimulates induction of KLF2 via the MEK5/ERK5/MEF2 pathway, which ultimately leads to MEF2A binding to and transactivating the KLF2 promoter [76]. KLF2 has been reported to be essential for the anti-inflammatory and antithrombotic functions of the endothelium [77]. The mechanisms by which KLF2 achieve its anti-inflammatory function are multiple and include inhibition of NFκB, activator protein-1 (AP-1), and activating transcription factor 2 (AP-2). Thus, the ROS produced in preeclamptic placenta could be involved in the activation of MEF2A in SMCs. On the other hand in the ECs, MEF2A activation could be part of an adaptive response seeking to protect the cells against inflammation and thrombosis (two characteristics of PE).

**NFYA.** associates with a dimer composed of NF-YB, and NF-YC subunits, forming a trinucleotide binding to DNA. The complex recognizes the pentanucleotide CCAAT, a motif present in the promoter regions of many genes [78]. The DNA interaction of the complex occurs through NFYA, suggesting a role as the regulatory subunit. ROS play also an important role in NFY regulation [79]. When oxidized, NFYB forms homodimers remaining localized in the cytoplasm, as a consequence the formation of the trimer and subsequent DNA binding is impaired. NF-Y is known to interact with several TFs to mediate the synergistic activation of specific classes of promoters. The most frequent TFs partners of NFY include: SREBP, SP1, KLF5, OCT-1 and E2F1. NFY seems to be also involved in the response to cell stress. Thus, NFY directly controls the expression of TFs genes such as P53 (DNA-damage), XBPI, CHOP/DDIT3 (ER stress), and HSF1 (Heat shock), [78]. The role of NFY in the regulation of genes involved in the response to cell stress could represent a link between this TF and PE. In this sense, NFYA and OCT-1 (another TF which appears over-represented in our analysis) synergistically regulate a P53-independent induction of GADD45 subsequently to DNA-damage [80]. The GADD45 stress sensor protein has been suggested to be the link between placental stress and the pathogenesis of PE through the induction of FL-1. Thus in stressed placental explants

---

**Transcription Factors in the Preeclamptic Placenta**
GADD45a initiated a signaling cascade culminating in FLt-1 induction [81].

In addition to the TFs identified by our bioinformatic TFBS analysis, some of the genes consistently modified in the preeclamptic placenta encode TFs. Among the up-regulated genes we found: LIMD1, BHLHE40, VDR, CEBPA, BCL6, ARID3A and NRIP1. Among the down-regulated genes: TFDP2, ZFAND5, BHLHE41, and NR2F1.

LIMD1 inhibits E2F-mediated transcription, and suppresses the expression of the majority of genes with E2F1-responsive elements [82]. The up-regulation of this TF in the preeclamptic placenta seems coherent with the detection of an over-representation of TFBS for E2F1 among the down-regulated genes. On the other hand, LIMD1 has been recently involved in the regulation of the hypoxia response through a mechanism involving HIF1α degradation [83]. LIMD1 up-regulation in the preeclamptic placenta might result from a feed-back mechanism aiming to regulate the transcriptional activity of the HIF complex. BHLHE40 (DEC1/STRA13) is another TF up-regulated in PE, known to be expressed in the cytotrophoblasts and fibroblast cells of the placenta [84]. Its gene expression is regulated by various extracellular stimuli, such as growth factors, serum starvation, hormones, nutrients, cytokines, and hypoxia through HIF-1α activation. CEBPA (CCAAT/enhancer-binding protein alpha) coordinates proliferation arrest and the differentiation of trophoblastic cells [85]. CEBPA is known to activate the expression of the leptin gene [86]. Thus, the up-regulation of CEBPA is probably related to the increased expression of leptin (one of the most consistently modified genes in the PE placenta). BCL6 mediates transcriptional repression and interacts with components of histone deacetylase co-repressor complexes including N-CoR and SMRT [87]. It is involved in a multiple biological processes including: regulation of inflammatory response; negative regulation of cell growth; negative regulation of transcription, response to DNA damage stimulus, negative regulation of B cell apoptosis. It has been speculated that up-regulation of BCL6 in the preeclamptic placenta could be related to deregulated DNA-damage response, cell cycle arrest, cell survival and immune response in trophoblast cells [5]. ARID3A is a nuclear matrix-associated TF that stimulates immunoglobulin heavy chain (IgH) expression and Cyclin E1/E2F-dependent cell cycle progression. [88,89]. NRIP1 (also known as RIP140) has been shown to bind and repress the transcriptional activity of several nuclear receptors including the estrogen receptors, the peroxisome proliferator-activated receptors, the vitamin D receptor, thyroid hormone receptors, and estrogen-related receptors [90]. NRIP1 has a major role as co-regulator of genes involved in lipid and glucose metabolism, in heart, skeletal muscle, and liver. Its biological role in the placenta is currently unknown. However, we found in our study that the most significantly up-regulated pathways concern the peroxisome proliferators-activated receptor and lipids biosynthesis. Its implication in placental inflammation through its cooperation with NFkB is also possible. TFDP2 is a member of the E2F/DP family [91]. As mentioned above, it binds DNA cooperatively with E2F family members. The down-regulation of TFDP2 implies impaired E2F1 driven transcription, and seems to be coherent with the fact that TFBS for E2F1 are over-represented among the down-regulated genes in the PE placenta. ZFAND5 plays a role in the regulation of NFkB activation and apoptosis. Over-expression of ZFAND5 sensitizes cells to TNF-induced apoptosis [92]. BHLHE41 (DEC2/SHARP) is associated with the regulation of apoptosis, circadian rhythm and the response to hypoxia [93]. This TF binds to HIFs and promotes HIF proteasomal degradation by serving as the HIF-presenting factor to the proteasome independently from pVHL (von Hippel-Lindau tumor suppressor), hypoxia and the ubiquitination machinery. BHLHE41 therefore determines the intrinsic instability of HIF proteins to act in parallel to, and cooperate with, oxygen levels [94]. Therefore down-regulation of BHLHE41, is probably related to the up-regulation of hypoxia responsive genes in the PE placenta. NR2F1 (COUP-TF1) is a member of the orphan subfamily of nuclear receptors required for multiple physiologic and biologic functions, including heart and vascular system function and cholesterol/lipid homeostasis [95]. Little is known about a putative role of NR2F1 in the placenta. A study identified NR2F1 as a repressor of the hLHR (Luteinizing hormone receptor) gene transcription in JAR cells (issued from a human placental choriocarcinoma), [96]. In the placenta LH mediates gonadotropin signals and triggers intracellular responses that participate in maturation and function of the gonads as well as the regulation of steroidogenesis and gametogenesis. Nevertheless, we observe that TFBS for COUP are over-represented in the list of down-regulated genes in the PE placenta.

Another TF worth mentioning here is STOX1 (storkhead box 1). To date only two PE susceptibility genes have been identified (ACVR2A and STOX1). Of these, STOX1 encodes a winged-helix TF showing great similarity with the FOX family of TFs [97]. STOX1 has been found to be involved in trophoblast dysfunction in PE. Over-expression of STOX1 in the JEG-3 choriocarcinoma cell line (as a model for trophoblasts), deregulates many genes which are also modified in the preeclamptic placenta [98]. Transgenic mice over-expressing the human version of STOX1 develop a syndrome similar to severe human PE. During pregnancy, the mice undergo a steep increase in blood pressure, develop proteinuria and renal histology reveals accumulation of fibrin [99]. Here, we have compared the transcriptome of the JEG-3 cells over-expressing STOX1 and the list of consistently modified genes in PE and found a significant correlation (data not shown). Genes such as LEP, ENG, EBI3, FSTL1, SPAG4, LHB, TMEM45A, GCLM, TFDP2, or TSPAN12 that we find consistently modified in PE, are also transcriptionally modified in the JEG-3 over-expressing STOX1. The microarrays analyzed in the present study do not reveal any significant modifications in the transcriptional levels of STOX1. However, STOX1 is known to be post-transcriptionally regulated. When phosphorylated by Akta, the STOX1 protein is inhibited from entering the nucleus and subsequently degraded by ubiquitination. In the absence of phosphorylation STOX1 is addressed to the nucleus [97]. As the STOX1 DNA-binding domain shows great similarity to FOX transcription factors it has been proposed that STOX1 binds to the FOX binding sites in the promoters of target genes. In our analysis FOX binding sites are detected as over-represented among the consistently down-regulated genes.

Having identified a set of TFs which are likely involved in the transcriptional modifications of the preeclamptic placenta, we investigated the putative interactions within them. The interactomics analysis using the STRING software showed that most of these TFs present close interactions. Moreover, by extending the interaction network we found that many of them were strongly connected with a pivotal TF: EP300. This protein is ubiquitously expressed and functions as a scaffolding actor between the TFs and the RNA polymerase II. It functions also as a histone acetyltransferase that regulates transcription via chromatin remodeling [100]. Among others, it mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein [101]. EP300 has been also identified as a co-activator of HIF-1α, and, thus, plays a role in the stimulation of hypoxia-induced genes such as VEGF [102]. The loss of one functional
copy of the gene causes a rare disease in infants, the Rubinstein-Taybi syndrome. This disease is characterized by growth retardation, dysmorphic features, skeletal abnormalities and mental retardation [103]. Interestingly, three of the babies out of the seven reported cases, were born from women who developed preeclampsia during the pregnancy [104]. This suggests that there could be an association between EP300 heterozygotic deleterious mutations and PE. The interaction of EP300 with most of the TFs identified in our study enhances its possible implication in PE.

In summary, our study has identified a number of TFs which could be key regulators of the changes in gene expression observed in the preeclamptic placenta. This allows developing hypothesis about the molecular mechanisms at work in the diseased placenta. However, there are a number of limitations of our study which must be taken into consideration. We have drawn a list of consistently modified genes in PE from the publicly available microarray data sets. That corresponds to only six studies from a total of 20 published microarray studies on preeclampsia. Unfortunately, the datasets corresponding to the majority of studies have not been deposited in public databases. Moreover, the authors do not provide in their manuscripts complete lists of modified genes. The access to more datasets would have increased the statistical power of the study, and presumably identified even more striking commonalities. Another aspect to consider is that these microarray experiments were done on placental samples which are composed of different cell types. This heterogeneity can cause noise that disturbs the correct prediction of a co-regulated gene set, and hence of the TFs involved in their regulation. Finally, we arbitrarily chose to limit the size of the promoters to be analyzed to 1200 bp. We postulated that the TFs regulating the activity of the modified genes would bind TFBS close to the TSS (-1000/+200 bases). If we had chosen other promoter lengths we might get different results. In a previous study published in 2006, Vasarhelyi et al analyzed the promoters of genes found to be modified in preeclamptic placentas [105]. They reported an over-representation of TFBS corresponding to NFκB, SREBP and E47. Except for NFκB, the TFs identified in their study are different to those reported here, these differences being probably due to the data used for the studies. Vasarhelyi et al extracted data from a number of studies performed between years 2002 to 2005 [47,106,107,108]. At that time, microarrays offered only a partial covering of the human genome. Thus, we used more recent data corresponding to microarrays with full coverage of the human genome.

Despite all these caveats our study allowed to identify a number of TFs involved in PE. Although a few of them are found to be consistently modified in the preeclamptic placenta at the transcriptional level, many of the TFs identified by our study (NFκB, CREB, ARNT, SP1, E2F1, NFXA...) are regulated by post-transcriptional mechanisms. These post-transcriptional modifications (acytelyation, methylation, phosphorylation, sumoylation, etc...) can be triggered by cellular stresses which are known to be associated with PE such as hypoxia, inflammation, oxidative stress, DNA-damage, etc… The validity of the hypothesis raised by our bioinformatic study need to be confirmed by experimental studies analyzing the implication of these TFs (including their post-transcriptional modifications) in both, in vitro models and in vivo in preeclamptic placentas.

Supporting Information

Table S1 Complete list of consistently up-regulated genes in the preeclamptic placenta. The lists of up-regulated genes for each of the six preeclamptic placenta microarrays analyzed in this study were confronted using the GENOMATIX list comparison tool (Genomatix Software GmbH, Munich, Germany). This allowed to identify those genes which were consistently up-regulated. Those showing similar modification in at least 4 studies were considered relevant and included in a final list of consistently up-regulated genes. (XLSX)

Table S2 Complete list of consistently down-regulated genes in the preeclamptic placenta. The lists of down-regulated genes for each of the six preeclamptic placenta microarrays analyzed in this study were confronted using the GENOMATIX list comparison tool (Genomatix Software GmbH, Munich, Germany). This allowed to identify those genes which were consistently down-regulated. Those showing similar modification in at least 4 studies were considered relevant and included in a final list of consistently down-regulated genes. (XLSX)

Author Contributions
Conceived and designed the experiments: DV FM. Performed the experiments: DV RC FM. Analyzed the data: DV RC FM. Wrote the paper: DV FM.

References
1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R (2010) Pre-eclampsia. Lancet 376: 631–644.
2. Sibai BM (2012) Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol 206: 470–475.
3. James JL, Whitley GS, Cartwright JE (2010) Pre-eclampsia: fitting together the puzzle pieces. J Matern Fetal Neonatal Med 23: 156–161.
4. Wang A, Rana S, Krasnow M, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24: 147–158.
5. Louwen F, Muschol-Steinmetz C, Reinhard J, Reitter A, Yuan J (2012) A new tool for the analysis of promoter microarray data: An overview of promoter microarray analysis tools. Curr Protoc Biotech 8: Unit 8.14.1-8.14.17.
6. Tapia A, Vilos C, Marin JC, Criscito HB, Devoto L (2011) Bioinformatic detection of E47, E2F1 and SREBP1 transcription factors as potential regulators of genes associated to acquisition of endometrial receptivity. Reprod Biol Endocrinol 9: 14.
7. Teti R, Gilbert W (2006) The Regulatory Genome: Gene Regulatory Networks in Development and Evolution; Burlington M, editor. San Diego, USA: Academic Press.
8. Sitras V, Paulsen RH, Grounaas H, Leivik J, Hausen TA, et al. (2009) Differential placental gene expression in severe preeclampsia. Placenta 30: 424–433.
9. Meng T, Chen H, Sun M, Wang H, Zhao G, et al. (2012) Identification of differential gene expression profiles in placentas from preeclamptic pregnancies versus normal pregnancies by DNA microarrays. OMICS 16: 301–311.
10. Tsi S, Hardison NE, James AH, Moninger-Reif AA, Bischoff SR, et al. (2011) Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals dysregulation of iNOS and other immune signalling pathways in placenta. Placenta 32: 175–182.
11. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, et al. (2007) Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe preeclampsia. Placenta 28: 487–497.
12. Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, et al. (2011) Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biomed Online 9: 107.
13. Wimm VD, Gormley M, Paquet AC, Kjaer-Sorensen K, Kramer A, et al. (2009) Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology 150: 452–462.
14. Suzuki Y, Yamashita R, Sugano S, Nakai K (2004) DFBSS, DataBase of Transcriptional Start Sites: progress report 2004. Nucleic Acids Res 32: D78–81.
15. Plocota M, Konrostynski M, Przewlocki R (2010) Identification of cis-regulatory elements in the mammalian genome: the cREMaG database. PLoS One 5: e12465.
41. Kotani T, Iwase A, Ino K, Sumigama S, Yamamoto E, et al. (2009) Activator protein-2 regulates mouse placental lactogen gene expression. Mol Cell Endocrinol 160: 183–192.

40. Shi D, Kellems RE (1998) Transcription factor AP-2gamma regulates murine placental lactogen gene expression. Mol Cell Biol 18: 1541–1549.

38. Werling U, Schorle H (2002) Transcription factor gene AP-2 gamma essential for normal placentation and epigenetic mechanisms collaborate to control SERPINA3 expression and regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem 277: 17499–17506.

37. Richardson BD, Langland RA, Bachurski CJ, Richards RG, Kessler CA, et al. (2007) Cullins in human intra-uterine growth restriction: expressional and protein expression changes. Pancreas 34: 480–487.

36. Takacs P, Kauma SW, Sholley MM, Walsh SW, Dinsmoor MJ, et al. (2001) Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in vascular endothelial cells. J Appl Physiol 91: 1753–1764.

35. Cooke CL, Davidge ST (2002) Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol 282: C395–402.

34. Kruger I, Vollmer M, Simmons DG, Elsasser HP, Philipsen S, et al. (2007) Increased circulating lipid peroxides in severe preeclampsia activate NF-kappaB and upregulate ICAM-1 in vascular endothelial cells. FASEB J 21: 1553–1563.

33. Nakada E, Walley KR, Nakada T, Hu Y, von Dadelszen P, et al. (2009) Toll-like receptor-3 stimulation upregulates sFLT-1 production by trophoblast cells. Placenta 30: 774–779.

32. Tan NY, Khachigian LM (2009) Sp1 phosphorylation and its regulation of gcna-1 promoter. J Biol Chem 284: 10632–10639.

31. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, et al. (2003) AT1 receptor antagonist reduces the invasion of a human extravillous trophoblast cell line. Mol Cell Endocrinol 193: 131–141.

30. Richardson BD, Langland RA, Bachurski CJ, Richards RG, Kessler CA, et al. (2007) Cullins in human intra-uterine growth restriction: expressional and protein expression changes. Pancreas 34: 480–487.

29. Flajollet S, Poras I, Carosella ED, Moreau P (2009) RREB-1 is a transcriptional activating factor that recruits the human lepton gene promoter. J Biol Chem 274: 49253–49261.

28. O'Connor DJ, Lu X (2000) Stress signals induce transcriptionally inactive E2F-1. Cell 100: 229–238.

27. Cooke CL, Davidge ST (2002) Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in vascular endothelial cells. J Appl Physiol 91: 1753–1764.

26. Takacs P, Kauma SW, Sholley MM, Walsh SW, Dinsmoor MJ, et al. (2001) Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in vascular endothelial cells. J Appl Physiol 91: 1753–1764.

25. Nakada E, Walley KR, Nakada T, Hu Y, von Dadelszen P, et al. (2009) Toll-like receptor-3 stimulation upregulates sFLT-1 production by trophoblast cells. Placenta 30: 774–779.

24. Vaughan JE, Walsh SW (2012) Activation of NF-kappaB in trophoblast tissues. Am J Physiol 299: C1753–1764.

23. Hayden MS, Ghosh S (2012) NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26: 203–234.

22. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: protein interactions and functional Modules from 997 experimentally inferred interaction networks. Nucleic Acids Res 39: D561–568.

21. Sanchez-Esmer E, Botella LM, Velasco B, Langa C, Bernabeu C (2002) Endothelins are expressed in placental villi and in vitro models of human placental villi. Mol Cell Endocrinol 150: 4376–4385.

20. Aerts S, Van Loo P, Thijs G, Mayer H, de Martin R, et al. (2005) TOUCAN 2: identification of transcription factors associated with sets of co-regulated genes. Bioinformatics 21: 415–424.

19. O'Connor DJ, Lu X (2000) Stress signals induce transcriptionally inactive E2F-1. Cell 100: 229–238.

18. Ozanne SE, Cory R, Kuchel H, Ewens WJ, Wathes DC (2008) The expression of inflammation-related cytokines in placental villi is upregulated in pregnancies complicated by preeclampsia. Placenta 29: 696–704.

17. Barcena A, Kapidzic M, Muench MO, Gormley M, Scott MA, et al. (2009) Oxford Bioinformatics Ltd. BH Haven, Oxfordshire OX3 0BW, UK. 2005. Identification of retinoic acid receptor target genes in mouse embryos. Bioinformatics 25: 435–442.

16. Wolberger C, Qi J, Seraphin B, Kuriyan J (2005) Crystal structure of human p300/CBP found that p300/CBP has a unique mechanism of histone acetyltransferase activity. Proc Natl Acad Sci USA 102: 13972–13977.

15. Steibl A, Bierich JR, Hoth G, Dietz A, Krug A, et al. (2006) Low expression of the beta 2-adrenergic receptor is associated with the decreased expression of the beta 2-adrenergic receptor in preeclampsia. J Hypertens 24: 1753–1764.

14. Somogyi I, Ugale B, Brandes RP, et al. (2007) AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107: 1632–1639.

13. Flajollet S, Poras I, Carosella ED, Moreau P (2009) RREB-1 is a transcriptional activating factor that recruits the human lepton gene promoter. J Biol Chem 274: 49253–49261.

12. O'Connor DJ, Lu X (2000) Stress signals induce transcriptionally inactive E2F-1. Cell 100: 229–238.

11. Sanchez-Esmer E, Botella LM, Velasco B, Langa C, Bernabeu C (2002) Endothelins are expressed in placental villi and in vitro models of human placental villi. Mol Cell Endocrinol 150: 4376–4385.

10. Nakada E, Walley KR, Nakada T, Hu Y, von Dadelszen P, et al. (2009) Toll-like receptor-3 stimulation upregulates sFLT-1 production by trophoblast cells. Placenta 30: 774–779.

9. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, et al. (2003) AT1 receptor antagonist reduces the invasion of a human extravillous trophoblast cell line. Mol Cell Endocrinol 193: 131–141.

8. Wolberger C, Qi J, Seraphin B, Kuriyan J (2005) Crystal structure of human p300/CBP found that p300/CBP has a unique mechanism of histone acetyltransferase activity. Proc Natl Acad Sci USA 102: 13972–13977.

7. O'Connor DJ, Lu X (2000) Stress signals induce transcriptionally inactive E2F-1. Cell 100: 229–238.

6. Wolberger C, Qi J, Seraphin B, Kuriyan J (2005) Crystal structure of human p300/CBP found that p300/CBP has a unique mechanism of histone acetyltransferase activity. Proc Natl Acad Sci USA 102: 13972–13977.

5. Nakada E, Walley KR, Nakada T, Hu Y, von Dadelszen P, et al. (2009) Toll-like receptor-3 stimulation upregulates sFLT-1 production by trophoblast cells. Placenta 30: 774–779.

4. Vaughan JE, Walsh SW (2012) Activation of NF-kappaB in trophoblast tissues. Am J Physiol 299: C1753–1764.

3. Nakada E, Walley KR, Nakada T, Hu Y, von Dadelszen P, et al. (2009) Toll-like receptor-3 stimulation upregulates sFLT-1 production by trophoblast cells. Placenta 30: 774–779.

2. O'Connor DJ, Lu X (2000) Stress signals induce transcriptionally inactive E2F-1. Cell 100: 229–238.

1. O'Connor DJ, Lu X (2000) Stress signals induce transcriptionally inactive E2F-1. Cell 100: 229–238.
Transcription Factors in the Preeclamptic Placenta

70. Lin SY, Black AR, Kostic D, Pajovic S, Hoover CN, et al. (1996) Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol 16: 1668–1675.

71. Pillai S, Kovalc S, Chellappan S (2010) Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res 70: 4931–4940.

72. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S (2006) Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp1 and Sp3. J Biol Chem 281: 36760–36767.

73. Pothoff MJ, Olson EN (2007) ME2F: a central regulator of diverse developmental programs. Development 134: 4131–4140.

74. Oishi Y, Manabe I, Imai Y, Harata K, Horikoshi M, et al. (2010) Regulatory polymorphism in transcription factor KLF5 at the ME2F element alters the response to angiotensin II and is associated with human hypertension. FEBS J 274: 1789–1798.

75. Dong JT, Chen C (2009) Essential role of KLF3 transcription factor in cell proliferation activity orientation and its implications for human diseases. Cell Mol Life Sci 66: 2971–2976.

76. van Thienen JV, Fedderus JO, Dekker RJ, Rohlena J, van IJzendoorn GA, et al. (2006) Shear stress sustains atheroprotective endothelial KLF2 expression more potently than stasis through mRNA stabilization. Cardiovasc Res 72: 213–220.

77. Atkins GB, Jain MK (2007) Role of Kruppel-like transcription factors in endothelial biology. Circ Res 100: 1686–1693.

78. Dailini D, Gatta R, Mantovani R (2012) NF-Y and the transcriptional activation of CCAAT promoters. Crit Rev Biochem Mol Biol 47: 29–49.

79. Nakashita H, Bhat-Nakshatri P, Currie RA (1996) Subunit association and DNA binding activity of the heterotrimeric transcription factor NF-Y is regulated by cellular redox. J Biol Chem 271: 28704–28709.

80. Jin S, Fan F, Fan W, Zhao H, Tong T, et al. (2001) Transcription factors Oct-1 protein alpha. J Biol Chem 270: 28887–28891.

81. Foxler DE, Bridge KS, James V, Webb TM, Mee M, et al. (2012) The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to the ubiquitin-proteasome pathway. J Biol Chem 287: 4931–4940.

82. Sharp TV, Munoz F, Bourboulia D, Presneau N, Darai E, et al. (2004) LIM domains-containing stress activates Gadd45a signaling and p63 in placental explants. J Cell Physiol 228: 362–370.

83. Atkins GB, Jain MK (2007) Role of Kruppel-like transcription factors in endothelial biology. Circ Res 100: 1686–1693.

84. Sharp TV, Muzaf F, Bourboulia D, Presneau N, Darai E, et al. (2004) LIM domains-containing stress activates Gadd45a signaling and p63 in placental explants. J Cell Physiol 228: 362–370.

85. Kasper LH, Lerach S, Wang J, Wu S, Jeevan T, et al. (2010) CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J 29: 3660–3672.

86. Rigourd V, Chauvet C, Chelbi ST, Rebourcet R, Mondon F, et al. (2008) STOX1 overexpression in chorioncarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. PLoS One 3: e3905.

87. Reimer T, Koczan D, Gerber B, Richter D, Thiesen HJ, et al. (2012) Inhibition of VEGF transcription through blockade of the hypoxia inducible factor–alpha pathway by azaguanine. Cancer Res 72: 5249–5252.

88. Reimer T, Koczan D, Gerber B, Richter D, Thiesen HJ, et al. (2002) Preeclampsia-Like Symptoms Induced in Mice by Fetoplaclental Expression of STOX1 Are Reversed by Aspirin Treatment. Hypertension 61: 662–668.

89. Eckner R, Arabz Y, Ewen M, Sellers W, Livingston JM (1994) The adenovirus E1A-associated p500-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family. Cold Spring Harb Symp Quant Biol 59: 85–95.

90. Kasper LH, Lerach S, Wang J, Jeevan T, et al. (2010) CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J 29: 3660–3672.

91. Kwon HS, Kim DR, Yang EG, Park YK, Ahn HC, et al. (2012) Inhibition of VEGF transcription through blockade of the hypoxia inducible factor–alpha pathway by azaguanine. Cancer Res 72: 5249–5252.

92. Rubinstein JH, Taybi H (1963) Broad thumbs and toes and facial abnormalities. Possible mental retardation syndrome. Am J Dis Child 105: 391–403.

93. Usui K, Nakamura T, Yamanaka S, Nishimura H, et al. (2011) A novel SNP in the gene for the human luteinizing hormone receptor. J Biol Chem 286: 6430–6437.

94. Rigourd V, Chauvet C, Chelbi ST, Rebourcet R, Mondon F, et al. (2008) STOX1 overexpression in chorioncarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. PLoS One 3: e3905.

95. Reimer T, Koczan D, Gerber B, Richter D, Thiesen HJ, et al. (2012) Preeclampsia-Like Symptoms Induced in Mice by Fetoplaclental Expression of STOX1 Are Reversed by Aspirin Treatment. Hypertension 61: 662–668.

96. Eckner R, Arabz Y, Ewen M, Sellers W, Livingston JM (1994) The adenovirus E1A-associated p500-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family. Cold Spring Harb Symp Quant Biol 59: 85–95.

97. Kasper LH, Lerach S, Wang J, Jeevan T, et al. (2010) CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J 29: 3660–3672.

98. Kwon HS, Kim DR, Yang EG, Park YK, Ahn HC, et al. (2012) Inhibition of VEGF transcription through blockade of the hypoxia inducible factor–alpha pathway by azaguanine. Cancer Res 72: 5249–5252.

99. Rubinstein JH, Taybi H (1963) Broad thumbs and toes and facial abnormalities. Possible mental retardation syndrome. Am J Dis Child 105: 391–403.

100. Tsai AG, Dosssett CJ, Walton CS, Cramer AE, Eng PA, et al. (2011) Exon deletions of the EP300 and CREBBP genes in two children with Rubinstein-Taybi syndrome detected by aCGH. Eur J Hum Genet 19: 43–49.

101. Usui K, Nakamura T, Yamanaka S, Nishimura H, et al. (2011) A novel SNP in the gene for the human luteinizing hormone receptor. J Biol Chem 286: 6430–6437.

102. Kwon HS, Kim DR, Yang EG, Park YK, Ahn HC, et al. (2012) Inhibition of VEGF transcription through blockade of the hypoxia inducible factor–alpha pathway by azaguanine. Cancer Res 72: 5249–5252.

103. Rubinstein JH, Taybi H (1963) Broad thumbs and toes and facial abnormalities. Possible mental retardation syndrome. Am J Dis Child 105: 391–403.

104. Tsai AG, Dosssett CJ, Walton CS, Cramer AE, Eng PA, et al. (2011) Exon deletions of the EP300 and CREBBP genes in two children with Rubinstein-Taybi syndrome detected by aCGH. Eur J Hum Genet 19: 43–49.